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Abstract: Background: Research over the past decade has focused on the role of Klotho as a
cardio protective agent that prevents the effects of aging on the heart and reduces the burden
of cardiovascular disease CVD. The role of the interaction between fibroblast growth factor
23-(FGF-23)/Klotho in Klotho-mediated actions is still under debate. The main objective was to
ascertain the potential use of plasmatic Klotho and FGF23 as markers for CKD-associated cardiac
disease and mortality. Methods: This was a prospective analysis conducted in an outpatient
diabetic nephropathy clinic, enrolling 107 diabetic patients with stage 2–3 CKD. Patients were
divided into three groups according to their left ventricular mass index and relative wall thickness.
Results: Multinomial regression analysis demonstrated that low Klotho and higher FGF-23 levels
were linked to a greater risk of concentric hypertrophy. In the generalized linear model (GLM),
Klotho, FGF-23 and cardiac geometry groups were statistically significant as independent variables of
cardiovascular hospitalization (p = 0.007). According to the Cox regression model, fatal cardiovascular
events were associated with the following cardiac geometric classifications; eccentric hypertrophy
(p = 0.050); concentric hypertrophy (p = 0.041), and serum phosphate ≥ 3.6 mg/dL (p = 0.025),
FGF-23 ≥ 168 (p = 0.0149), α-klotho < 313 (p = 0.044). Conclusions: In our population, Klotho and
FGF23 are associated with cardiovascular risk in the early stages of CKD.
Keywords: klotho; FGF-23; CKD; CVD; LVMI
1. Introduction
Aging is the result of a complex interplay between genetics, environment and lifestyle.
It encompasses intricate body physiologic alterations that hamper organs’ function and compromises
their long-term viability. As major regulators of many vital physiologic processes, the kidneys are
often the first organs to express the effects of aging. Reduced glomerular filtration rate (GFR) and/or
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diminished production of several hormones and communication mediators usually appear first and
are the triggers of major consequent alterations that frequently result in chronic kidney disease (CKD),
anemia, osteoporosis and left ventricular hypertrophy (LVH) [1–4].
CKD is known to be related to cardiac overload, which reconfigures the architecture and
physiology of the myocardium, inducing hypertrophy and fibrosis [4,5]. These alterations appear
in the early stages of the disease and are aggravated with worsening kidney disease, compromising
cardiac function and inducing the development of cardiovascular disease (CVD) [5]. Nowadays,
kidney-associated CVD is a major public health concern in western societies, representing the ninth
leading cause of death in the USA [6]. Markers of prognosis are needed, as are effective therapeutic
strategies aimed at blocking these degrading cascades.
Research over the past decade has focused on the role of Klotho as a cardio protective agent that
prevents the effects of aging on the heart and reduces the burden of CVD [7,8]. Whether the interaction
of FGF23 and Klotho is essential for Klotho-mediated actions is still under debate, and clarification is
needed as reports in the literature are inconsistent [9–11]. In line with the recent work of Drew and
collaborators [12], the present work used a pool of 107 CKD patients to ascertain the potential use of
plasmatic Klotho, FGF23 or both, as markers for CKD-associated cardiac disease and to discuss their
eventual use as therapeutic targets in CKD. A secondary objective was to evaluate the role of mineral
metabolism markers of the left ventricle, such as FGF-23 and α-Klotho in geometric form.
2. Results
This study enrolled one hundred and seven (107) consenting patients with stage 2–3 CKD,
who were cleared of all exclusion criteria. The mean age was 57.2 ± 7.1 years (range: 41–68) and the
mean LVMI level was 99.31 ± 23.45 g/m2 (range: 67–189).
The demographic and clinical parameters of the study subjects are presented in Table 1.
Table 1. Patient demographic and clinical characteristics at baseline.
Characteristics Values
Number of patients, n 107
Gender (f/m) 40/67
BMI (Kg/m2) 26.04
Age (years) 57.19 ± 7.05
Hb (g/dL) 12.97 ± 1.83
Albumin (g/dL) 4.27 ± 0.48
eGFR (mL/min) 52.89 ± 20.15
ACR (µg/mg) 181.89 ± 33.83
Pi (mg/dL) 3.99 ± 0.85
PTH (pg/mL) 113.11 ± 74.65
Calcium (mg/dL) 9.48 ± 0.68
FGF-23 (RU/mL) 135.04 ± 135.23
1,25 (OH)2 Vitamin D (pg/mL) 21.21 ± 7.36
α-Klotho (pg/mL) 331.10 ± 171.06
IL-6 (pg/mL) 5.71 ± 3.80
Oxidized LDL (U/L) 39.91 ± 19.55
HOMA-IR 1.84 ± 1.67
HbA1c (%) 7.67 ± 1.47
LVMI (g/m2) 99.31 ± 23.45
Systolic BP (mmHg) 126.59 ± 16.53
Diastolic BP (mmHg) 78.58 ± 9.98
Diabetes-related CKD evolution time (months) 73.8 ± 8.7
Values are presented as mean ± standard deviation.
In terms of allocation of patients into groups according to their LVH and RWT values, 41 (38.3%)
had normal geometry, 38 (35.5%) had eccentric hypertrophy and 28 (26.2%) had concentric hypertrophy.
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All the assessed variables, except age and BMI, showed significant differences between the three
groups (Table 2).
Table 2. Patient demographic and clinical characteristics at baseline according to level of
cardiac hypertrophy.
Group 1
Normal
Geometry
n = 41
Group 2
Eccentric
Hypertrophy
n = 38
Group 3
Concentric
Hypertrophy
n = 28
p
Age (years) 56.12 ± 7.35 57.29 ± 7.27 58.61 ± 6.21 NS
eGFR (mL/min/1.73 m2) 62.89 ± 20.58 47.13 ± 15.18 46.06 ± 20.10 <0.001
BMI (Kg/m2) 26.3 ± 1.08 26.8 ± 0.42 27.2 ± 0.64 NS
Hb (g/dL) 13.57 ± 1.73 12.98 ± 1.81 12.98 ± 1.81 0.003
Pi (mg/dL) 3.32 ± 0.64 4.76 ± 0.54 4.13 ± 0.75 <0.001
PTH (pg/mL) 74.16 ± 49.67 104.07 ± 63.26 182.41 ± 73.07 <0.001
ACR (µg/mg) 122.13 ± 90.60 193.50 ± 144.86 253.64 ± 91.30 <0.001
IL-6 (pg/mL) 2.93 ± 1.82 8.47 ± 3.22 10.09 ± 2.42 <0.001
α-Klotho (pg/mL) 399.17 ± 143.72 344.82 ± 53.52 160.82 ± 60.70 <0.001
FGF-23 (RU/mL) 66.75 ± 39.66 113.06 ± 54.20 264.84 ± 72.96 <0.001
[1,25(OH)2D3] (pg/mL) 25.78 ± 4.49 21.88 ± 6.80 18.60 ± 5.22 <0.001
Systolic BP (mmHg) 124.2 ± 14.2 121.1 ± 15 125.5 ± 16.5 0.057
Diastolic BP (mmHg) 71.2 ± 10.4 71.9 ± 11.8 69.6 ± 11.6 NS
Heart rate (bpm) 67 ± 12 70 ± 13 69 ± 11 NS
LV end-diastolic volume (mL) 120 ± 17 162 ± 32 118 ± 20 0.005
LV end-systolic volume (mL) 42 ± 10 62 ± 23x 45 ± 15 <0.001
LV mass/body surface area (g/m2) 96 ± 11 132 ± 22 134 ± 20 NS
RWT 0.38 ± 0.3 0.37 ± 0.06 0.46 ± 0.03 NS
RAS inhibitor/or ACEI (%) 78.7 80.7 88.9 NS
Calcium channel blockers with
renoprotective action (%) 35.6 48.6 52.3 NS
Diabetes-related CKD evolution time
(months) 75.5 ± 9.6 71.7 ± 7.3 74.1 ± 8.7 NS
LV, left ventricular; LVH, left ventricular hypertrophy; RWT, relative wall thickness; ARB, angiotensin-converting
inhibitor; ACEI, angiotensin-converting enzyme inhibitor; NS means without statistical significance.
A simple linear regression analysis (Table 3) revealed that LVMI levels were inversely proportional
to α-Klotho (r = −0.440, p = 0.0001), and directly proportional to Pi (r = 0.672, p = 0.005), and to FGF-23
(r = 0.622, p = 0.0001).
Table 3. Simple linear regression analysis between LVMI and other parameters.
Variable R p-Value
Gender 0.741 0.354
Age 0.243 0.223
BMI 0.480 0.650
eGFR −0.227 0.060
Hb −0.317 0.973
Pi 0.672 0.005
PTH 0.520 0.199
ACR 0.427 0.075
IL-6 0.737 0.087
α-Klotho −0.440 0.0001
FGF-23 0.622 0.0001
Multinomial regression analysis demonstrated that diminished eGFR and elevated Pi levels
were associated with a greater risk of eccentric hypertrophy but not with concentric hypertrophy.
In fact, hyperphosphatemia seemed to increase the risk of eccentric hypertrophy threefold. Contrarily,
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low α-Klotho and higher FGF-23 levels were linked with a greater risk of concentric hypertrophy,
with higher Klotho levels associated with a 26% lower risk (Table 4).
Table 4. Clinical characteristics’ correlation with eccentric or concentric left ventricular hypertrophy by
multinomial logistic regression analysis.
Variable Eccentric Hypertrophy Concentric Hypertrophy
OR 95% CI p OR 95% CI p
α-Klotho 1.005 0.97–1013 0.186 0.737 0.603–0.972 0.031
Gender 1.670 0.341–8.174 0.527 1.986 0.905–2.009 0.063
Age 1.095 0.970–1.235 0.142 1.053 0.821–1.349 0.685
eGFR 0.959 0.921–0.999 0.043 0.769 0.622–1.050 0.085
Pi 2.859 2.238–5.693 0.003 1.115 0.958–2.318 0.063
PTH 0.980 0.960–1.001 0.058 0.994 0.969–1.020 0.664
ACR 1.005 0.999–1.011 0.131 0.977 0.945–1.011 0.184
FGF-23 1.008 0.996–1.020 0.219 1.031 1.008–1.205 0.009
[1,25 (OH)2 D3] 0.904 0.726–1.126 0.366 0.529 0.263–1.061 0.073
Hb 1.040 0.686–1.577 0.852 0.307 0.295–1.001 0.068
IL-6 1.255 0.836–1.885 0.274 1.443 0.984–2.858 0.208
*Reference category: No Hypertrophy.
Figure 1 shows Kaplan–Meier survival curves in patients with normal left ventricular geometry,
eccentric hypertrophy and concentric hypertrophy. A survival table is also given with the number
of patients at risk. Censored subjects are indicated as tick marks. Comparison between the groups
using the log-rank test revealed the highest risk group is with concentric hypertrophy (log rank = 9.422;
p = 0.009). In our study, the cause of mortality was coronary and cerebrovascular disease in eccentric
and concentric hypertrophy.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 13 
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Figure 1. Cardiovascular mortality according to left ventricular geometry (Kaplan–Meier Analysis).
In the generalized linear model (GLM), Klotho, FGF-23 and cardiac geometry groups were
statistically significant as independent variables of cardiovascular hospitalization (p = 0.007).
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The results showed that the α-Klotho group (<313), compared to the group at ≥313, had higher
odds of hospitalization ORa = 1.491, p = 0.014. In addition, the FGF-23 group (≥168), compared
to the group at <168, had higher odds of hospitalization, ORa = 1.689, p = 0.004. The concentric
hypertrophy group compared to the no hypertrophy group had higher odds of hospitalization,
ORa = 4.889, p = 0.023. The optimized model as a function of α-Klotho groups, eGFR, age, gender,
phosphorus, PTH, IL6, vitamin D, FGF-23 and cardiac geometry groups allowed for a final and
statistically significant model (p < 0.001), which included Klotho groups, FGF-23 and cardiac geometry
variables. The area under the receiver operating characteristic curve (ROC curve) for this optimized
model was 0.980 (p < 0.001), revealing an elevated discriminating capacity of the model. The obtained
estimates showed that the group with low levels of α-Klotho (ORa = 1.320, p = 0.024), higher levels of
FGF-23 (ORa = 1.105, p = 0.012) and the concentric hypertrophy group (ORa = 2.284, p = 0.041) had
greater odds of cardiovascular hospitalization (Table 5).
Table 5. Predictive factors of cardiovascular hospitalization.
Initial Model Optimized Model
ORa 95%CI for ORa p ORa 95%CI for ORa p
α-Klotho groups
<313 1.491 1.207–2.125 0.014 11.320 1.061–1.456 0.024
≥313 Ref. Ref.
FGF-23 groups
≥168 1.689 1.004–3.500 0.004 1.105 1.000–1.763 0.012
<168 Ref. Ref.
Concentric Hypertrophy 4.889 3.372–5.512 0.023 2.284 1.970–4.720 0.1
Eccentric Hypertrophy 3.360 0.692–4.890 0.064 1.410 0.984–2.523 0.075
No Hypertrophy Ref. Ref.
p-value (model) 0.007 <0.001
Area under ROC (p-value) - 0.980 (p < 0.001)
ORa: Adjusted odds ratio, 95%CI for OR: 95% confidence interval for the odds ratio, Ref: Category versus the one is
making comparisons.
According to Cox regression models (Table 6), fatal cardiovascular events were associated with the
following cardiac geometric classifications; eccentric hypertrophy (p = 0.050); concentric hypertrophy
(p = 0.041), and Pi ≥ 3.6 (p = 0.025), FGF-23 ≥ 168 (p = 0.0149), α-klotho < 313 (p = 0.044).
Table 6. Factors independently associated with cardiovascular mortality.
HRa 95%CI for ORa p-Value
Pi
<3.6 Ref.
≥3.6 1.079 1.015–3.409 0.025
α-Klotho groups
<313 2.377 1.488–11.585 0.044
≥313 Ref.
FGF-23 groups
≥168 2.046 1.008–8.249 0.014
< 168 Ref.
Concentric 3.254 1.035–6.699 0.041
Eccentric 1.112 1.070–3.850 0.050
No Hypertrophy Ref.
HRa: Adjusted hazards ratio, 95%CI for HR: 95% confidence interval for the hazard ratio, Ref: Category that is
being used to make comparisons against. The other variables included in the model, but that presented no statistical
significance were: age, gender, PTH, 1.25(OH)2D3, Hg, ACR, IL-6, stratified renal disease stage 2 (60–89) and
3 (30–59).
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ROC curve analysis demonstrated that α-Klotho < 313 and FGF-23 ≥ 168 are the best cut-off
values associated with cardiovascular mortality (AUC = 0.793; 95% CI 0.695–0.892), (AUC = 0.758;
95% CI 0.638–0.879), respectively.
3. Discussion
The current study shows that both Klotho and FGF23 are independently altered and associated
with concentric hypertrophy in CKD patients, thus being suitable as indicators of cardiac disease
in this population. Particularly, it provides evidence that CKD-associated cardiac hypertrophy
correlates with reduced eGFR and soluble Klotho and Vitamin D levels, and is indicative of a
generalized pro-inflammatory status, as evidenced by increased levels of IL-6, ACR, PTH, P and
FGF23. Furthermore, it shows that concentric hypertrophy in particular is associated with a more
severe phenotype with a shorter survival rate.
CKD is a very well-established inducer of cardiac hypertrophy, as it increases the heart burden
in an attempt to accommodate kidney failure (recently reviewed by Lullo et al.) [13]. Aiming to
correlate the alteration of the LV geometry with sudden cardiac death risk, Lang and collaborators
proposed a 4-pattern classification of LV geometry based on both LVMI and relative wall thickness
(normal geometry, concentric remodeling, eccentric hypertrophy and concentric hypertrophy) [14].
According to this classification, concentric hypertrophy confers the highest risk, followed by eccentric
hypertrophy and concentric remodeling [15]. Therefore, our study is likely to be the first to corroborate
the 4-pattern cardiac hypertrophy classification in a population of CKD patients.
As recently argued by Neyra and Hu, there is an urgent need to identify sensitive and/or more
specific diagnostic and prognostic biomarkers for CKD [16]. In fact, while very sensitive as an indicator
of cardiac hypertrophy, the 4-pattern classification is very unspecific and must be combined with
other parameters to provide clues on the etiology of the cardiac remodeling. In this line, our results
substantiate others in the literature showing that Klotho and vitamin D are consistently reduced in
CKD patients, while Pi, FGF-23 and PTH are consistently elevated [17–22]. Moreover, and unlike
what was observed by Tanaka and collaborators, these associations were significant in all CKD
patients, particularly between Klotho and cardiac hypertrophy [11]. Altogether, these data support the
interpretation of the LV morphological results in light of the abovementioned physiological parameters
as both diagnostic biomarkers of CKD and useful follow up parameters in these patients. They have
been proved to not only have diagnostic value but also sensitive prognostic potential. For instance,
mortality data previously collected revealed significant differences among the three cardiac geometry
groups. Patients with concentric hypertrophy tended to have worse survival rates than patients without
left ventricular hypertrophy. We demonstrated that, after adjustment for cofounders, CKD patients
with low serum α-Klotho levels (≤313 pg/mL) and high serum FGF-23 levels (≥168 pg/mL) are at
high risk of adverse cardiovascular outcomes.
Furthermore, in the generalized linear model, concentric hypertrophy was found to independently
predict patient survival, with increased risk of hospitalization [23–25].
Regarding the interaction between α-Klotho and FGF-23, our results seem to corroborate
those of Grabner et al., suggesting independent roles for each protein. These authors
demonstrated that FGF-23-mediated activation of FGFR4 in cardiomyocytes stimulates phospholipase
Cc/calcineurin-NFAT signaling, independently triggering LV hypertrophy [26]. Moreover, and in
agreement with this observation, both Faul et al. and Shibata et al. reported a statistically significant
association between serum FGF-23 levels, LV hypertrophy and cardiac systolic function [17,27],
mediated by an increase in α-actin in cardiac muscle cells, with an increase in expression of LVH
markers, such as fetal heavy chain β-myosin, and a drop in adult heavy chain α-myosin.
The cardiac hypertrophic effects of FGF-23 are mediated by FGFR-dependent activation of the
calcineurin nuclear factor of the activated T-cell (NFAT) signaling cascade, but do not require Klotho
as a co-receptor [26].
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As to Klotho, the exact pathophysiologic mechanisms behind its association with CKD progression
are yet to be identified. This protein, which is mainly produced by the kidneys, consists of
a long extracellular domain connected to a small intracellular C-terminal domain through a
membrane-spanning segment. Its signaling properties depend upon the segment of the protein
involved [7,28]. In fact, while membranous Klotho is a co-receptor for fibroblast growth factor 23
(FGF-23) along with the FGF receptor (FGFR), acting as a downregulator of phosphate metabolism,
soluble Klotho results from the cleavage of the extracellular domain of the membranous primordial
protein and exerts its action as a paracrine factor [7,8]. The specific actions of Klotho are still being
investigated, but it appears that Klotho relies on its enzymatic properties to act as a major regulator
of ion transport and growth factor signaling [8]. For instance, Klotho has been shown to reduce
stress-induced cardiac hypertrophy by inhibiting cardiac TRPC6 channels in cardiomyocytes, as well
as to stimulate TRPV5 receptors in the renal distal tubules, thus allowing the regulation of phosphate
metabolism independently of calcium levels [9,10]. Its role in uremic myocardiopathy is not yet
fully understood. Studies performed on animal models showed there is an association between
ventricular hypertrophy and increased expression of TRPC6 (transient receptor potential canonical 6)
channels, whose expression is regulated by a wide range of redundant mechanisms. Recently, Xie et al.
demonstrated that Klotho may inhibit cardiac TRPC6 channels, thereby protecting the myocardium
against excessive/pathological remodeling [7,29].
The elucidation of Klotho- and FGF-23-mediated functions in CKD paved the way for the
development of targeted therapies. For instance, Di Marco et al. showed that the progression of
cardiac hypertrophy and cardiac fibrosis could be reduced by antibody-mediated blockage of the FGF
receptor [30], which would also help revert the CKD-associated mineral and bone disorders, as both
the decrease in vitamin D and the increase in PTH are FGF-23-mediated [28,29,31]. On the other hand,
Xie et al. observed that the administration of soluble Klotho to CKD patients prevented the progression
of uremic cardiomyopathy [29] and Yin and collaborators proposed that kidney fibrosis might be
abrogated by a fine-tuned control of the pro-fibrotic TGFβ functions [32]. At this point, it has become
evident that a concerted plan of action that accommodates these new findings is urgently needed,
aiming to provide CKD patients with a better diagnosis, follow up, prognosis and treatment.
In our study, the group with concentric hypertrophy had a higher cardiovascular mortality when
compared to the group with eccentric hypertrophy and normal left ventricular geometry. Elevated
levels of FGF-23 are implicated in elevated cardiovascular mortality in CKD when adjusted for the
traditional risk factors and other mineral metabolism markers. The role of FGF-23 in cardiovascular
mortality is not yet fully understood [33]. Pi et al. recently reported a relationship between the
elevation of FGF-23 and activation of the renin-angiotensin-aldosterone system (RAAS). Activation
of the RAAS through angiotensin II may explain this relationship between elevated FGF-23 and CV
mortality [34].
Despite acknowledging the small sample size, the sparse number of cardiovascular events and
the limited statistical power of these analyzes as the main limitations of this study, the current study
presents preliminary results of a long term project. Notwithstanding this, the role that these new
markers may play in cardiovascular morbidity and mortality in this particular population with diabetes
and mild to moderate CKD is evident in the study.
Subsequent research is expected to evaluate the role of Klotho and FGF-23 in left ventricular
diastolic dysfunction and progression to heart failure in patients with chronic renal disease.
4. Materials and Methods
4.1. Subjects
This prospective analysis was conducted in the outpatient diabetic nephropathy (DN) clinic of
the Centro Hospitalar Universitário do Algarve in Faro, Portugal, from 2012 to 2017, enrolling a total
of 107 (female = 40) adult diabetic patients with stage 2–3 CKD. Before its implementation, the study
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was granted ethical approval by the Hospital’s Ethics Committee (November 2011), ensuring that all
principles of the Declaration of Helsinki of 1973 (revised in 2000) were followed. All procedures were
implemented after obtaining patients’ written informed consent. Diabetes was classified as per the
American Diabetes Association guidelines [35].
The exclusion criteria were: age > 65 years; previous CVD–defined as a history of one or more
of the following: non-fatal myocardial infarction, angina pectoris (stable or unstable), stroke or
transient ischemic attacks, peripheral vascular disease or congestive heart failure; atrial fibrillation,
severe coronary heart disease associated with the presence of a wall motion abnormality by two
dimensional echocardiography, left bundle branch block, severe valvular heart disease confirmed
with echocardiogram; changes in the GFR of more than 30% in the previous 3 months, changes in
antihypertensive therapy 2 weeks before study, uncontrolled hypertension (BP ≥ 140/90 mmHg);
albumin/creatinine ratio (ACR) ≥ 500 mg/g assessed on two occasions with an interval of 3 months;
estimated glomerular filtration rate (eGFR) ≤ 29 mL/min/1.73 m2 or ≥ 89 mL/min/1.73 m2;
parathyroid hormone (PTH) ≥ 350 pg/mL; phosphorus (Pi) > 5.5; type 1 diabetes; non-diabetic
renal disease; neoplastic or infectious diseases.
Medical history, laboratory data, and current therapy were collected during the initial visit.
4.2. BP and Echocardiographic Measurements
The blood pressure (BP) was determined with oscillometric methods, with the patient in dorsal
decubitus. Three measurements were taken with an interval of 5 min between them.
Echocardiographic evaluation was obtained using standard M mode and two-dimensional images
(Vivid 7 Dimension-GE Healthcare Ultrasound; GE Healthcare, Waukesha, WI). Offline analysis was
obtained using the workstation Echopac PC’08 version 7.0.0 GE Vingmed Ultrasound (GE Healthcare),
and the measurements were consistently obtained by the same physician. Images were digitally stored
and analyzed by two independent experienced cardiologists. Quality control procedures included
blind rereading and patient reexamination to allow assessment of intra-reader variability, inter-reader
variability, and intra-patient variability. An average of three measurements was made for each variable.
Patients were divided into three groups according to the left ventricular mass index (LVMI) and
the relative wall thickness (RWT) values, calculated using the following equations:
(1) Regression equation from Penn convention:
LV mass = 1.04 ([LVIDD + PWTD + IVSTD]3 − [LVIDD]3) − 13.6 g (1)
where LVIDD = left ventricular internal diameter in diastole, PWTD = posterior wall thickness in
diastole and IVSRD = inter-ventricular septum thickness in diastole. LVMI was then obtained by
dividing LV mass by body surface area.
RWT = 2(PWT)/LVDD (2)
where PWT is the posterior wall thickness and LVDD is the left ventricle diastolic diameter.
LVH and RWT were used to categorize LV geometry: normal (no LVH and normal RWT),
eccentric hypertrophy (LVH and normal RWT), and concentric hypertrophy (LVH and increased
RWT). Patients were classified as having LVH if they had a left ventricular mass index (LVMI)of
100 g/m2 in women and 131 g/m2 in men [36], and RWT was considered to be increased if it was
≥0.45 according to the study by Chen et al. [37].
4.3. Follow-up
The Centro Hospitalar Universitário do Algarve – Unidade de Faro outpatients’ DN clinic is the
Algarve’s reference center for nephrology and guarantees a regular follow-up for patients with DN.
Patients with a more severe condition are monitored every 3 months and those with a milder disease
every 6 months. Mean duration of follow-up was 33.8 ± 8.6 months.
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4.4. Blood Measurements
Fasting samples were drawn from all subjects and plasma was frozen at −80 ◦C in order to
measure eGFR, phosphorus (Pi), calcium (Ca), parathyroid hormone (PTH), glycated hemoglobin
(HbA1c), insulin resistance index, interleukin-6 (IL-6), fibroblast growth factor-23 (FGF23),
1,25(OH)2D3 (vitamin D), soluble α-Klotho (Klotho) and oxidized low density lipoprotein (oxLDL).
Serum levels of vitamin D (1.25 dihydroxicolecalciferol) were determined by radioimmunoassay
(IDS, Boldon, UK). The vitamin D levels were the average of three measurements conducted in
winter, spring and summer. Serum levels of FGF23 were quantified using the enzyme-linked
immunosorbent assay Human FGF-23 (C-Term) enzyme-linked immunoassay (ELISA) kit (Cat. #60-6100
ImmunotopicsInc, San Clemente, CA, USA). Soluble α-Klotho serum levels were determined by ELISA
using the Human soluble α-Klotho kit (Code no- 27998, IBL – Immuno-Biologial Laboratories Co.,
Ltd., Gunma, Japan), by adapting the manufacturer’s instructions to the Triturus microplate automatic
system (Grifols S.A., Barcelona, Spain). Two blood samples were collected for the validation of the
circadian variability of Klotho and FGF-23, P and Ca were assayed by the ARCHITECT c and the
AEROSET Systems (Abbott Diagnostics Division, Abbott Laboratories Abbott Park, IL). IL-6 and oxLDL
determination was performed with a sandwich ELISA kit (eBioscience, San Diego, CA, USA). HbA1c
and PTH levels were measured using a spectrophotometry technique and electrochemiluminescent
immunoassay (ECLIA), respectively. PTH concentrations were measured on an Immulite 2000 Intact
PTH assay (Cat. #L2KPP2, Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA). The degree
of insulin resistance was estimated using the homeostasis model assessment (HOMA-IR) described by
Matthews et al. [38]. Serum creatinine was assayed by the multigent creatinine enzymatic method,
using the ARCHITECT® device (Abbott Diagnostics Division, Abbott Laboratories Abbott Park, IL;
USA). We estimated the GFR according to the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) Equation [39].
4.5. Urine Measurements
The ACR was determined from a first-morning urine collected on the 1st and the 8th day of
the inclusion period. Urinary albumin and creatinine were determined immediately using the DCA
2000® albumin/creatinine assay system (Bayer Diagnostica, Barcelona, Spain) kit. A laboratory
immunoturbidimetric assay was used for albumin and creatinine determinations and the results are
reported as ACR (µg/mg). Intra individual variation of ACR was assessed in 8 of the 16 subjects for
7 consecutive days.
4.6. Cardiovascular Events
The primary cardiovascular outcome of this study was cardiovascular mortality. Deaths were
confirmed by review of autopsy reports, death certificates, medical records, or information obtained
from the next of kin or family members and classified, according to its cause, as cardiovascular or
non-cardiovascular death. Cardiovascular deaths were defined as caused by coronary heart disease,
heart failure, peripheral vascular disease and cerebrovascular disease.
The secondary outcome evaluated the predictive factors of cardiovascular
hospitalizations/admissions. These were classified upon discharge, considering only admissions
caused by coronary heart disease (myocardial infarction, stable or unstable angina pectoris),
congestive heart failure, peripheral vascular disease and cerebrovascular disease (stroke or transient
ischemic attacks) based on recent international guidelines (Kavousi, Leening, Nanchen, et al.,
2014) [40]. According to the presence or absence of cardiovascular hospital admission during the
study period, our population was divided into two groups: G-1—with cardiovascular hospitalization
(n = 26), and G-2—without cardiovascular hospitalization (n = 81).
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4.7. Statistical Analysis
Continuous variables are presented as mean and standard deviation and categorical variables
are expressed as percentages and compared using the chi-squared test. Demographic and clinical
factors associated with LVH were evaluated by ANOVA and the Kruskal–Wallis H test, respectively.
Patients’ demographic and clinical characteristics at baseline were grouped according to their level of
cardiac hypertrophy.
Simple linear regressions were used to investigate possible correlations between these variables
and LVMI, while multivariable nominal logistic regression identified factors associated to eccentric
and concentric hypertrophy, using as a reference, patients with normal geometry.
We evaluated time to fatal CV end point by Kaplan–Meier survival analysis compared by log-rank
test among the three patterns of LV geometry for measuring patients’ survival rate and a comparison
between the three groups was based on the log rank test. The null hypothesis was rejected below the
5% level. Statistical analysis was performed using SPSS (version 17.0; SPSS, Chicago, IL, USA).
The generalized linear model (GLM) for binary dependent variables was used (binomial
distribution) with a logistic link function. The exponentials of the model parameters were the adjusted
odds ratio (ORa) to other variables of the model. The test was used to determine whether Klotho,
FGF-23 and cardiac geometry were important predictive factors in the determination of cardiovascular
hospitalization. Prior to conducting the GLM, we calculated the median level of Klotho serum and
FGF-23 in the current study population. The subjects were categorized in the following classes:
Klotho (≥313 pg/mL or <313 pg/mL), and FGF-23 (≥168 RU/mL or <168 RU/mL).
The independent variables associated with cardiovascular mortality were identified by Cox
regression models. Variables included in these models were: age (<65; ≥65), gender, median:
PTH (<138; ≥138), Pi (<3.6; ≥3.6), 1.25(OH)2D3 (≥21;< 21), α-klotho (<313; ≥313), FGF-23 (<168;
≥168), ACR (<181; ≥181), IL-6 (<6; ≥6), stratified renal disease (60–89-stage 2; 30–59 stage 3) and
cardiac geometric classification (normal; eccentric hypertrophy; concentric hypertrophy).
We used the receiver operating characteristic (ROC) curve to identify klotho and FGF-23 cut-offs
associated with the highest cardiovascular death in this population.
5. Conclusions
The role of emerging factors like FGF-23 and Klotho in cardiovascular risk in both the early and
late stages of chronic kidney disease is not entirely understood. The entire process involves direct and
indirect mechanisms that contribute to this high cardiovascular risk. Moreover, these proteins seem to
have independent roles in the pathophysiology of cardiovascular disease and CKD and have recently
been considered relevant potential therapeutic agents in this disease.
The early identification of CKD onset and risk stratification of CKD progression and/or
CKD-related complications are essential for early treatment of CKD patients to ameliorate their
comorbidity burden, particularly CVD, and prevent the development of ESRD.
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ARB Angiotensin-converting inhibitor
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eGFR Estimated glomerular filtration rate
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